35 results
POS AM
ADIL
Adial Pharmaceuticals Inc
24 Jun 22
Prospectus update (post-effective amendment)
5:11pm
test, neither CDER nor CDRH is bound to accept our planned submission package even if the data is positive. We have been instructed by CDER and CDRH … appear similar to those outlined in the package insert for the approved indications and to those reported in the literature for treatment in chronic
POS AM
ADIL
Adial Pharmaceuticals Inc
24 Jun 22
Prospectus update (post-effective amendment)
5:02pm
was reached as to the development path for the genetic test, neither CDER nor CDRH is bound to accept our planned submission package even if the data … to those outlined in the package insert for the approved indications and to those reported in the literature for treatment in chronic liver disease
POS AM
evyx46 2uju
6 Apr 21
Prospectus update (post-effective amendment)
12:00am
POS AM
dcrpm6snxraqwzkq
6 Apr 21
Prospectus update (post-effective amendment)
12:00am
POS AM
c9hjj
22 Apr 20
Prospectus update (post-effective amendment)
5:05pm
POS AM
99uwlk8jdr 3b4fnan
22 Apr 20
Prospectus update (post-effective amendment)
5:04pm
424B3
9wmep8rcawfy4dcl3biq
2 Apr 19
Prospectus supplement
6:19am
8-K
EX-1.1
15cp1h07qx19
26 Feb 19
Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
8:10am